Theseus Pharmaceuticals, Inc. Contracts & Agreements
25 Contracts & Agreements
- Business Finance (5 contracts)
- Business Operations (1)
- Human Resources (8)
- Intellectual Property (1)
- Mergers & Acquisitions (1)
- Real Estate (1)
- Uncategorized (8)
- Agreement and Plan of Merger, by and among Concentra Biosciences, LLC, Concentra Merger Sub II, Inc. and Theseus Pharmaceuticals, Inc., dated December 22, 2023 (Filed With SEC on December 22, 2023)
- Consulting Agreement, by and between Theseus Pharmaceuticals, Inc. and David Kerstein, M.D., effective as of December 7, 2023 (Filed With SEC on December 4, 2023)
- Separation and Release Agreement, by and between Theseus Pharmaceuticals, Inc. and David Kerstein, M.D., effective as of December 7, 2023 (Filed With SEC on December 4, 2023)
- Consulting Agreement, by and between Theseus Pharmaceuticals, Inc. and Timothy P. Clackson, Ph.D., effective as of December 7, 2023 (Filed With SEC on December 4, 2023)
- Separation and Release Agreement, by and between Theseus Pharmaceuticals, Inc. and Timothy P. Clackson, Ph.D., effective as of December 7, 2023 (Filed With SEC on December 4, 2023)
- Amended and Restated Outside Director Compensation Policy (Filed With SEC on August 10, 2023)
- Description of Registrants Securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 10, 2022)
- Form of Underwriting Agreement (Filed With SEC on September 30, 2021)
- Lease Agreement, dated September 16, 2021, by and between Theseus Pharmaceuticals, Inc. and MIT 314 Main Street Leasehold LLC (Filed With SEC on September 30, 2021)
- 2021 Employee Stock Purchase Plan and form of subscription agreement (Filed With SEC on September 30, 2021)
- 2021 Equity Incentive Plan and forms of equity agreements thereunder (Filed With SEC on September 30, 2021)
- Form of Indemnification Agreement (Filed With SEC on September 30, 2021)
- Form of Registrants Common Stock Certificate (Filed With SEC on September 30, 2021)
- Amended and Restated Investors Rights Agreement, dated January 22, 2021, by and among the Registrant and the other parties thereto (Filed With SEC on September 15, 2021)
- Offer Letter, dated July 1, 2021, by and between Theseus Pharmaceuticals, Inc. and Iain D. Dukes (Filed With SEC on September 15, 2021)
- Offer Letter, dated May 25, 2021, by and between Theseus Pharmaceuticals, Inc. and Kathy Yi (Filed With SEC on September 15, 2021)
- Offer Letter, dated September 10, 2021, by and between Theseus Pharmaceuticals, Inc. and Bradford D. Dahms (Filed With SEC on September 15, 2021)
- Offer Letter, dated September 10, 2021, by and between Theseus Pharmaceuticals, Inc. and Victor M. Rivera (Filed With SEC on September 15, 2021)
- Offer Letter, dated September 10, 2021, by and between Theseus Pharmaceuticals, Inc. and David C. Dalgarno (Filed With SEC on September 15, 2021)
- Offer Letter, dated September 10, 2021, by and between Theseus Pharmaceuticals, Inc. and William C. Shakespeare (Filed With SEC on September 15, 2021)
- Offer Letter, dated September 10, 2021, by and between Theseus Pharmaceuticals, Inc. and Timothy P. Clackson (Filed With SEC on September 15, 2021)
- Incentive Bonus Plan (Filed With SEC on September 15, 2021)
- License Agreement by and between ARIAD Pharmaceuticals, Inc. and Theseus Pharmaceuticals, Inc., dated as of June 13, 2018 (Filed With SEC on September 15, 2021)
- Compensation Program for Non-Employee Directors (Filed With SEC on September 15, 2021)
- 2018 Stock Plan and forms of equity agreements thereunder (Filed With SEC on September 15, 2021)
